If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at ...

Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...

Fintel reports that on December 12, 2025, Morgan Stanley maintained coverage of Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) with a Underweight recommendation. Analyst Price ...

Neutral sector-focused overview describing factual commentary surrounding Bristol Myers Squibb within the wider ...

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...

Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

A U.S. judge rejected Bristol Myers Squibb's bid to dismiss a lawsuit claiming it cheated shareholders of the former Celgene ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

This initiative marks among the BMS Foundation’s first grants in India to increase access to screening and build capacity to ...